TC
ACHN

TFS Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

TFS Capital’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-42,993
Closed -$332K – 1283
2016
Q1 		$332K Sell
42,993
-257,123
-86% -$1.88M 0.05% 613
2015
Q4 		$3.24M Buy
+300,116
New +$2.73M 0.35% 69
2014
Q4 		– Sell
-52,428
Closed -$523K – 1245
2014
Q3 		$523K Sell
52,428
-141,751
-73% -$1.32M 0.05% 579
2014
Q2 		$1.47M Buy
194,179
+180,495
+1,319% +$720K 0.12% 278
2014
Q1 		$45K Sell
13,684
-2,238
-14% -$7.83K ﹤0.01% 1309
2013
Q4 		$53K Buy
+15,922
New +$46.2K ﹤0.01% 1426

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TFS Capital's ACHN Position: Q2 2016 in Review

TFS Capital sold out of Achillion Pharmaceuticals (ACHN) in Q2 2016, closing a stake of 42,993 shares — an estimated $332K sold.

TFS Capital first reported a position in ACHN in Q4 2013 and held it in 6 quarters. The position peaked at $3.24M in Q4 2015. 147 funds tracked by Wall St. Rank hold ACHN as of Q2 2016.

  • TFS Capital reported no remaining Achillion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • TFS Capital sold 42,993 Achillion Pharmaceuticals shares in Q2 2016, an estimated $332K.
  • TFS Capital first reported a position in Achillion Pharmaceuticals in Q4 2013 and held it in 6 quarters.
  • TFS Capital's Achillion Pharmaceuticals position peaked at $3.24M in Q4 2015.
  • 147 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.